Anrun Biodegradable Punctal Plug Debuts at the 11th National Dry Eye Conference as JuMing Bio Advances Domestic Innovation in Dry Eye Therapy

(Source:Guanhao Biotech）

Source: Guanhao Biotech

The 11th National Dry Eye Academic Conference Concludes Successfully in Beijing

From October 24 to 26, 2025, the "11th China National Dry Eye Symposium, 9th China National Ocular Surface and Tear Film Disease Symposium, 9th China National Traditional Chinese Medicine Eye Care Symposium, and 4th Ophthalmic Drug Innovation Forum" was successfully held in Beijing.At this grand event, Juming Biotechnology, a subsidiary of Guanhao Biotech, made a stunning debut with its self-developed next-generation dry eye treatment product—Anrun® Biodegradable Punctal Plug, drawing widespread attention from the industry.

Break Foreign Monopolies, Achieve Domestic Production Breakthrough

2025·10

The successful development and launch of Anrun® Biodegradable Lacrimal Plug marks an important advancement in the field of dry eye treatment devices in China.This product, relying on Guanhao Biotech's deep technical accumulation in the field of regenerative materials, has broken through the long-standing dependence on foreign imports for such products, achieving the domestic production of key technologies. It provides Chinese dry eye patients with a safer and more clinically suitable new treatment option.

Anrun® Biodegradable Punctal Plug

Dry Eye Syndrome: A Highly Prevalent Disease in Urgent Need of Effective Treatment

Dry Eye Syndrome: A Growing Public Health Concern in China

Current Treatment Status and Pain Points

Currently, the treatment of dry eye mainly includes two categories: drug therapy and non-drug therapy.

Drug Therapy:Mainly using artificial tears, autologous serum, etc., supplemented by drugs that promote tear secretion or have anti-inflammatory effects. However, some artificial tears contain preservatives, which may damage the cornea and affect tear film stability with long-term use.

Non-pharmacological Treatment: Including warm compresses, punctal plugs, etc. Punctal plugs retain natural tears by closing the puncta, but traditional punctal plugs and semi-permanent plugs have problems such as easy displacement, easy shedding, strong irritation, and difficulty in size matching.

Anrun® Biodegradable Lacrimal Plug: Solving Treatment Challenges with Chinese Innovation

In response to the shortcomings of existing treatments, Guangzhou Juming Biotechnology Co., Ltd. has launched a new generation of Anrun® biodegradable punctal plugs. Made from FDA-approved biodegradable polymer material PLGA, the product features excellent biocompatibility and biodegradability, fully degrading and being absorbed within 6 months. It is suitable for temporary lacrimal duct occlusion therapy in surgery-induced dry eye conditions such as corneal refractive surgery and cataract surgery.

Product Advantages

Materials are safe and reliable:Made of FDA-approved biodegradable materials, with high biocompatibility and guaranteed safety;

Painless Comfort Experience:Non-invasive implantation, no exposed design, minimal foreign body sensation, high patient compliance;

Precise Blocking Cycle:6-month degradation cycle, perfectly matching the postoperative dry eye treatment window;

Flexible Adaptation Specifications:Offering multiple models, supporting single-unit sales to meet the varying punctal size requirements of different patients.

During the conference, the chairman of the conference, Professor Liu Zugu, and many attending experts visited the booth for exchange and guidance. The launch of Anrun® not only enriches the product portfolio for dry eye treatment in China but also demonstrates Guanhao Biotech's independent R&D strength and clinical transformation capabilities in the field of regenerative medical materials. In the future, the company will continue to promote the research and development and industrialization of innovative ophthalmic products, bringing more high-quality medical solutions to patients in China and even globally.